The US FDA again rejected Capricor Therapeutics’ Duchenne muscular dystrophy cell therapy deramiocel (a refusal for the second time), after the company had already narrowed the intended patient population within DMD. The agency cited “significant issues” with the trial package, according to the report. Capricor’s clinical program included two randomized studies that did not demonstrate deramiocel could meaningfully stave off heart failure or preserve upper-limb muscle function. The latest action keeps the therapy from reaching the market despite an earlier strategic attempt to align the development plan with a narrower indication.